Literature summary for 3.4.21.77 extracted from

Fitzpatrick, J.M.; Banu, E.; Oudard, S.
Prostate-specific antigen kinetics in localized and advanced prostate cancer (2009), BJU Int., 103, 578-587.

Search for more literature for 3.4.21.77

Application

Application	Comment	Organism
medicine	prostate-specific antigen is identified as a useful serum marker for assessing patients with prostate cancer during their follow-up. It is approved as a tool for detecting the disease in men aged over 50 years. There are limitations of a single prostate-specific antigen measurement, i.e. its low sensitivity and specificity in detecting prostate cancer, which may lead to the over-detection of cancers that pose little threat to health and/or life. Prostate-specific antigen kinetics (prostate-specific antigen velocity, doubling-time, half-time and progression) may be used to predict the outcome in both localized and advanced prostate cancer. Limitations of all prostate-specific antigen kinetics is the choice of many methods for calculation that can result in considerable variation in prediction and even in errors in patient management	Homo sapiens

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	-	-	-

Purification (Commentary)

Purification (Comment)	Organism
-	Homo sapiens

Source Tissue

Source Tissue	Comment	Organism	Textmining
additional information	prostate-specific antigen shows low specificity, besides increased levels in prostate cancer, prostate-specific antigen levels are also increased in benign prostatic hyperplasia, and in general inflammatory responses. Shows low sensitivity, prostate-specific antigen levels are highly variable over time, prostate-specific antigen poorly distinguishes indolent from aggressive cancers	Homo sapiens	-
prostate	-	Homo sapiens	-
semen	-	Homo sapiens	-
serum	in the serum of patients with prostate cancer	Homo sapiens	-

Synonyms

Synonyms	Comment	Organism
prostate-specific antigen	-	Homo sapiens
PSA	-	Homo sapiens

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)